JP2010522698A5 - - Google Patents

Download PDF

Info

Publication number
JP2010522698A5
JP2010522698A5 JP2010500036A JP2010500036A JP2010522698A5 JP 2010522698 A5 JP2010522698 A5 JP 2010522698A5 JP 2010500036 A JP2010500036 A JP 2010500036A JP 2010500036 A JP2010500036 A JP 2010500036A JP 2010522698 A5 JP2010522698 A5 JP 2010522698A5
Authority
JP
Japan
Prior art keywords
composition
methionine
weight percent
miu
suspension
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2010500036A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010522698A (ja
JP5587762B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CA2008/000563 external-priority patent/WO2008119160A1/en
Publication of JP2010522698A publication Critical patent/JP2010522698A/ja
Publication of JP2010522698A5 publication Critical patent/JP2010522698A5/ja
Application granted granted Critical
Publication of JP5587762B2 publication Critical patent/JP5587762B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2010500036A 2007-03-30 2008-03-27 膣内送達により子宮頸部異形成を治療するための二相性脂質小胞組成物および方法 Expired - Fee Related JP5587762B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US90932407P 2007-03-30 2007-03-30
US60/909,324 2007-03-30
PCT/CA2008/000563 WO2008119160A1 (en) 2007-03-30 2008-03-27 Biphasic lipid-vesicle composition and method for treating cervical dysplasia by intravaginal delivery

Publications (3)

Publication Number Publication Date
JP2010522698A JP2010522698A (ja) 2010-07-08
JP2010522698A5 true JP2010522698A5 (enExample) 2011-05-19
JP5587762B2 JP5587762B2 (ja) 2014-09-10

Family

ID=39807744

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010500036A Expired - Fee Related JP5587762B2 (ja) 2007-03-30 2008-03-27 膣内送達により子宮頸部異形成を治療するための二相性脂質小胞組成物および方法

Country Status (18)

Country Link
US (3) US8945529B2 (enExample)
EP (1) EP2134353B1 (enExample)
JP (1) JP5587762B2 (enExample)
KR (1) KR20090130081A (enExample)
AU (1) AU2008234364B2 (enExample)
CA (1) CA2681565C (enExample)
CY (1) CY1118794T1 (enExample)
DK (1) DK2134353T3 (enExample)
ES (1) ES2617063T3 (enExample)
HR (1) HRP20170250T1 (enExample)
HU (1) HUE033256T2 (enExample)
LT (1) LT2134353T (enExample)
MX (1) MX2009010405A (enExample)
PL (1) PL2134353T3 (enExample)
PT (1) PT2134353T (enExample)
SI (1) SI2134353T1 (enExample)
TW (1) TWI440477B (enExample)
WO (1) WO2008119160A1 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR3008900B1 (fr) * 2013-07-25 2018-03-30 Centre Nat Rech Scient Nanoparticules lipidiques multicompartimentees
US8986732B2 (en) * 2013-08-12 2015-03-24 Helix Biopharma Corporation Biphasic lipid-vesicle compositions and methods for treating cervical dysplasia by intravaginal delivery
US10159646B2 (en) * 2013-08-12 2018-12-25 Altum-Avro Pharma Partnership Biphasic lipid-vesicle compositions and methods for treating cervical dysplasia by intravaginal delivery
WO2015034925A1 (en) 2013-09-03 2015-03-12 Moderna Therapeutics, Inc. Circular polynucleotides
US20150147382A1 (en) * 2013-09-23 2015-05-28 Exir Nano Sina Company Topical liposomal compositions for delivering hydrophobic drugs and methods preparing same
EP3625345B1 (en) 2017-05-18 2023-05-24 ModernaTX, Inc. Modified messenger rna comprising functional rna elements
CA3064782A1 (en) * 2017-05-26 2018-11-29 Altum Pharmaceuticals Inc. Biphasix cannabinoid delivery
US11939601B2 (en) 2017-11-22 2024-03-26 Modernatx, Inc. Polynucleotides encoding phenylalanine hydroxylase for the treatment of phenylketonuria
CA3079428A1 (en) 2017-11-22 2019-05-31 Modernatx, Inc. Polynucleotides encoding ornithine transcarbamylase for the treatment of urea cycle disorders
MX2021003015A (es) 2018-09-13 2021-07-15 Modernatx Inc Polinucleotidos que codifican glucosa-6-fosfatasa para el tratamiento de la glucogenosis.
AU2019339430A1 (en) 2018-09-14 2021-04-29 Modernatx, Inc. Polynucleotides encoding uridine diphosphate glycosyltransferase 1 family, polypeptide A1 for the treatment of Crigler-Najjar Syndrome
CN118512401A (zh) * 2019-09-23 2024-08-20 迪迪艾斯研究公司 具有渗透促进剂的脂质囊泡组合物
WO2022204380A1 (en) 2021-03-24 2022-09-29 Modernatx, Inc. Lipid nanoparticles containing polynucleotides encoding propionyl-coa carboxylase alpha and beta subunits and uses thereof
US20240207444A1 (en) 2021-03-24 2024-06-27 Modernatx, Inc. Lipid nanoparticles containing polynucleotides encoding phenylalanine hydroxylase and uses thereof
BR112023019249A2 (pt) 2021-03-24 2023-12-12 Glo Pharma Inc Peptídeos e métodos para reduzir a pigmentação da pele
US20240207374A1 (en) 2021-03-24 2024-06-27 Modernatx, Inc. Lipid nanoparticles containing polynucleotides encoding glucose-6-phosphatase and uses thereof
US20240376445A1 (en) 2021-06-22 2024-11-14 Modernatx, Inc. Polynucleotides encoding uridine diphosphate glycosyltransferase 1 family, polypeptide a1 for the treatment of crigler-najjar syndrome
KR20240102989A (ko) * 2021-11-04 2024-07-03 글로 파마, 인크. 화장품 적용을 위한 방법 및 조성물
TW202412818A (zh) 2022-07-26 2024-04-01 美商現代公司 用於暫時控制表現之經工程化多核苷酸
WO2024130158A1 (en) 2022-12-16 2024-06-20 Modernatx, Inc. Lipid nanoparticles and polynucleotides encoding extended serum half-life interleukin-22 for the treatment of metabolic disease

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5358708A (en) * 1993-01-29 1994-10-25 Schering Corporation Stabilization of protein formulations
EP0711148B1 (en) * 1993-07-28 2000-08-30 Pharmaderm Laboratories Ltd. Biphasic multilamellar lipid vesicles
IN184589B (enExample) * 1996-10-16 2000-09-09 Alza Corp
US5993852A (en) 1997-08-29 1999-11-30 Pharmaderm Laboratories Ltd. Biphasic lipid vesicle composition for transdermal administration of an immunogen
US6656499B1 (en) * 1999-11-12 2003-12-02 Pharmaderm Laboratories, Ltd. Composition for transdermal and dermal administration of interferon-α
TWI272948B (en) * 2003-05-01 2007-02-11 Ares Trading Sa HSA-free stabilized interferon liquid formulations
EP1576952A1 (en) 2004-03-18 2005-09-21 OctoPlus Technologies B.V. Hydrogel microspheres with improved release profile

Similar Documents

Publication Publication Date Title
JP2010522698A5 (enExample)
MX2009010405A (es) Composicion en vesicula de lipido bifasico y metodo para tratar la displasia cervical mediante suministro intravaginal.
JP2021066744A5 (ja) ブプロピオンおよびデキストロメトルファンを含む組成物
US20220088201A1 (en) Linear polysaccharide based film products
JP2013515009A5 (enExample)
JP6444865B2 (ja) ダイズホスファチジルセリンで作られたコクリエート
JP2009507838A5 (enExample)
EP1537859A3 (en) Azithromycin dosage forms with reduced side effects
JP2013513612A5 (enExample)
JP2003506416A5 (enExample)
MXPA05010565A (es) Sistemas de suminsitro de farmacos que comprenden un ingrediente activo encapsulado.
JP2016535777A5 (enExample)
JP2011225596A5 (enExample)
CN109952101A (zh) 治疗高细胞因子血症和病毒感染的肥大细胞稳定剂
JP2013516493A5 (enExample)
JP2009544665A5 (enExample)
JP2019508437A (ja) モンテルカスト経粘膜フィルム
JP2013535472A5 (enExample)
JP2017514911A5 (enExample)
KR20140121394A (ko) 아캄프로세이트 제제, 그것의 사용 방법, 및 그것을 포함하는 조합
JP2014531470A5 (enExample)
ATE205387T1 (de) Selegilin enthaltende liposomale mittel
JP2012526099A5 (enExample)
JP2006508994A5 (enExample)
JP2011157395A5 (enExample)